Behavioral effects of AMI-193, a 5-HT(2A)- and dopamine D(2)-receptor antagonist, in the squirrel monkey
- PMID:11124389
- DOI: 10.1016/s0091-3057(00)00321-x
Behavioral effects of AMI-193, a 5-HT(2A)- and dopamine D(2)-receptor antagonist, in the squirrel monkey
Abstract
8-[3-(4-Fluorophenoxy) propyl]-1-phenyl-1,3,8-triazaspiro[4, 5]decan-4-one (AMI-193) was developed as a 5-HT(2A)-selective antagonist with in vivo activity suitable for behavioral studies. However, AMI-193 is a potent dopamine D(2)-receptor antagonist with low nanomolar affinity. Accordingly, D(2)-actions may contribute to its behavioral pharmacology. In the present study, the effects of AMI-193 on operant behavior were characterized in squirrel monkeys. In subjects trained under a fixed-interval (FI) schedule of stimulus termination, AMI-193 (0.003-0.01 mg/kg) dose-dependently decreased response rate. When administered in combination with cocaine (0.03-3. 0 mg/kg) or the selective dopamine uptake inhibitor, GBR 12909 (0. 03-3.0 mg/kg), the rate-decreasing effects of AMI-193 were reversed by both dopamine indirect agonists. In drug-discrimination experiments, AMI-193 (0.003 and 0.01 mg/kg) attenuated the discriminative-stimulus effects of cocaine. AMI-193 (0.003 and 0.01 mg/kg) also reduced response rate under a second-order schedule of i. v. self-administration of cocaine (0.1 mg/infusion). The profile of behavioral effects and drug interactions observed in the present study, in conjunction with the relatively high affinity of AMI-193 for dopamine D(2) receptors, suggests that its D(2)-antagonist effects play a prominent role in the behavioral pharmacology of AMI-193.
Similar articles
- Characterization of the effects of cocaine and GBR 12909, a dopamine uptake inhibitor, on behavior in the squirrel monkey.Howell LL, Byrd LD.Howell LL, et al.J Pharmacol Exp Ther. 1991 Jul 1;258(1):178-85.J Pharmacol Exp Ther. 1991.PMID:1677037
- Comparative behavioral pharmacology of cocaine and the selective dopamine uptake inhibitor RTI-113 in the squirrel monkey.Howell LL, Czoty PW, Kuhar MJ, Carrol FI.Howell LL, et al.J Pharmacol Exp Ther. 2000 Feb;292(2):521-9.J Pharmacol Exp Ther. 2000.PMID:10640288
- Pharmacological interactions between serotonin and dopamine on behavior in the squirrel monkey.Howell LL, Czoty PW, Byrd LD.Howell LL, et al.Psychopharmacology (Berl). 1997 May;131(1):40-8. doi: 10.1007/s002130050263.Psychopharmacology (Berl). 1997.PMID:9181634
- Serotonergic receptor subtypes and hallucinogen-induced stimulus control.Winter JC, Fiorella DJ, Timineri DM, Filipink RA, Helsley SE, Rabin RA.Winter JC, et al.Pharmacol Biochem Behav. 1999 Oct;64(2):283-93. doi: 10.1016/s0091-3057(99)00063-5.Pharmacol Biochem Behav. 1999.PMID:10515304Review.
- Behavior analysis and experimental pharmacology.Todorov JC.Todorov JC.Neurosci Biobehav Rev. 1981 Fall;5(3):307-14. doi: 10.1016/0149-7634(81)90025-7.Neurosci Biobehav Rev. 1981.PMID:7029359Review.
Cited by
- Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines.Winter JC.Winter JC.Psychopharmacology (Berl). 2009 Apr;203(2):251-63. doi: 10.1007/s00213-008-1356-8. Epub 2008 Nov 1.Psychopharmacology (Berl). 2009.PMID:18979087
- Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M.Knight AR, et al.Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. doi: 10.1007/s00210-004-0951-4. Epub 2004 Jul 30.Naunyn Schmiedebergs Arch Pharmacol. 2004.PMID:15322733
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources